Scientific research, clinical trials and patient feedback play a critical role in the development of our diagnostic tools.
Psyomics co-founder, Professor Sabine Bahn, head of the Cambridge Centre for Neuropsychiatric Research (CCNR), has dedicated more than 20 years of research to identifying differential biomarkers of mental health conditions. The Bahn laboratory is conducting an extensive research program to define the molecular basis of major neuropsychiatric disorders. Their focus is on schizophrenia, bipolar affective disorder, major depressive disorder and autistic and anxiety spectrum disorders.
The Delta Trial was a large-scale clinical trial launched in April 2018 as part of a research program conducted by CCNR and supported by Psyomics. The aim of the trial was to develop a more accurate way of diagnosing depression and bipolar disorder by combining an in-depth digital questionnaire with a blood spot test for biological markers.
Participants were asked to complete a comprehensive digital assessment to produce an in-depth symptom profile where diagnostic algorithms determined risk for bipolar disorder and depression. Study participants were also invited to use an at-home Dried Blood Spot (DBS) collection kit and were offered a telephone interview, the WHO Composite International Diagnostic Interview (CIDI). The digital diagnostic results were compared with the CIDI interview results to assess the accuracy of the new digital assessment tool.
Interest in the trial was high, attracting over 40,000 visitors to the site and over 5,000 participants enrolled. Engagement throughout the trial was above expected levels with over 1,800 DBS collected and 931 CIDI interviews completed. In total, more than 3,500 participants received a mental health report summarising a predicted diagnosis.
The Delta Trial was completed in 2020 and CCNR are now in the process of analysing the findings, with a number of publications under peer review. Subsequent papers will be published on the CCNR website.
Following the trial, Psyomics used the data insights, as well as extensive input from clinicians and patients, to further refine the diagnostic algorithms and expand the platform to develop the Censeo online mental health assessment, which mirrors a full psychiatric evaluation.
Our work is funded and supported by Cambridge Enterprise and a Horizon 2020 grant from the European Commission. In addition, Psyomics won an innovation contest with IC Tomorrow and AXA PPP to look at mental health awareness and prevention in the workplace, and won the Problem Solution category of the AXA PPP Health Tech & You Awards. We were also awarded a grant from the Technology Strategy Board to further develop technology for differentiating bipolar disorder from depression, which was used within the Delta Trial.